La prochaine rencontre, qui aura lieu le 10 novembre à Mila, permettra d'explorer comment pouvons-nous collectivement développer, encadrer et déployer des systèmes agentiques performants, fiables et sécuritaires en connectant chercheur·euse·s académiques, expert·e·s industriel·le·s et praticien·ne·s.
Les inscriptions sont ouvertes pour notre programme de 4 mois à temps plein, à Mila, conçu spécifiquement pour les fondateurs et fondatrices de la deep tech issus de parcours d'élite en STIM. Vous avez jusqu'au 21 novembre 2026 pour appliquer!
Le processus de demandes de supervision à Mila est maintenant ouvert! Vous pouvez appliquer dès maintenant à la maitrise de recherche ou Doctorat et joindre notre grande communauté de chercheur·euse·s à Mila pour l’automne 2027. Date limite : 1er décembre 2026
Nous utilisons des témoins pour analyser le trafic et l’utilisation de notre site web, afin de personnaliser votre expérience. Vous pouvez désactiver ces technologies à tout moment, mais cela peut restreindre certaines fonctionnalités du site. Consultez notre Politique de protection de la vie privée pour en savoir plus.
Paramètre des cookies
Vous pouvez activer et désactiver les types de cookies que vous souhaitez accepter. Cependant certains choix que vous ferez pourraient affecter les services proposés sur nos sites (ex : suggestions, annonces personnalisées, etc.).
Cookies essentiels
Ces cookies sont nécessaires au fonctionnement du site et ne peuvent être désactivés. (Toujours actif)
Cookies analyse
Acceptez-vous l'utilisation de cookies pour mesurer l'audience de nos sites ?
Lecteur Multimédia
Acceptez-vous l'utilisation de cookies pour afficher et vous permettre de regarder les contenus vidéo hébergés par nos partenaires (YouTube, etc.) ?
Farhood Farahnak
Alumni
Publications
Worldwide Innovative Network Consortium: Building a Common Global Cancer Database
This review shares the ongoing work of the global Worldwide Innovative Network (WIN) Consortium for Precision Medicine to synthesize emergin… (voir plus)g cancer treatment data and to define the requirements for a common global cancer database that can truly support precision oncology. We performed a narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured. The growth in molecular profiling technologies and the development of new targeted therapies are transforming cancer care. Tumors, regardless of tissue origin, are increasingly defined as composites of multiple, often rare, subgroups, each with distinct biology and likely response to specific therapies, based on multidimensional profiling of the tumor and its microenvironment. The solution lies in building vast databases that capture racial and ethnic diversity, reflected in genomic data, as well as diet and lifestyle factors that may have epigenetic impact on gene expression and post-translational modifications. A truly inclusive and informative data set must reflect global diversity, and there are multiple examples of demography-dependent differences in genomic signals. With members caring for and studying patients with cancer across five continents, WIN is actively exploring pathways to create a global cancer database, rich in clinical and molecular detail, granular enough for precise analysis, and large enough to power artificial intelligence-driven insights, provided appropriate data quality, validation, and governance frameworks are in place. This review surveys the current landscape and outlines practical paths forward to achieve this goal.
Prognostic data extraction harnessing a privacy-preserving large language model: a clinician-AI collaborative retrospective evaluation in head and neck oncology
Privacy regulations and limited expert-validation constrain the deployment of large language models (LLMs) for electronic health record stru… (voir plus)cturing. We evaluated locally deployed LLMs to extract 30 prognostic variables from 1,360 head and neck cancer reports (882 patients) using zero-shot prompting. A stratified 50-case subset was reviewed by three radiation oncologists (50 cases, 30 fields, 3 reviewers; 4,500 decisions) to form a majority-vote reference for Llama3.3-70B, which achieved 98.6% F1 with high clinician agreement and processed reports in 53 s/report. Among seven additional models (2.6B-70B) benchmarked against this reference, GPT-OSS-20.9B (F1 89.4%) and MedGemma-27B (F1 88.5%) performed best. Integrating LLM-extracted HPV status, smoking history, and Charlson Comorbidity Score into a multivariate Cox Proportional Hazards model (age, sex, T/N stage) improved disease-free survival (likelihood ratio test p = 0.014; ΔC-index + 0.071) and locoregional failure-free survival (p = 0.026; ΔC-index + 0.108) with 1,000-bootstrap internal validation. This clinician-AI collaborative evaluation shows that on-premises LLMs enable privacy-preserving and efficient tumour board support, longitudinal data curation, and outcome prediction.
While neural networks are capable of achieving human-like performance in many tasks such as image classification, the impressive performance… (voir plus) of each model is limited to its own dataset. Source-free domain adaptation (SFDA) was introduced to address knowledge transfer between different domains in the absence of source data, thus, increasing data privacy. Diversity in representation space can be vital to a model`s adaptability in varied and difficult domains. In unsupervised SFDA, the diversity is limited to learning a single hypothesis on the source or learning multiple hypotheses with a shared feature extractor. Motivated by the improved predictive performance of ensembles, we propose a novel unsupervised SFDA algorithm that promotes representational diversity through the use of separate feature extractors with Distinct Backbone Architectures (DBA). Although diversity in feature space is increased, the unconstrained mutual information (MI) maximization may potentially introduce amplification of weak hypotheses. Thus we introduce the Weak Hypothesis Penalization (WHP) regularizer as a mitigation strategy. Our work proposes Penalized Diversity (PD) where the synergy of DBA and WHP is applied to unsupervised source-free domain adaptation for covariate shift. In addition, PD is augmented with a weighted MI maximization objective for label distribution shift. Empirical results on natural, synthetic, and medical domains demonstrate the effectiveness of PD under different distributional shifts.